Latest Period
Q1 2026
Security Snapshot
AGIOS PHARMACEUTICALS, INC. - Common Stock, Par Value $0.001 per share (AGIO) Institutional Ownership
CUSIP: 00847X104
13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026
Institutions Reporting
230
Shares (Excl. Options)
63,038,208
Price
$33.83
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, Par Value $0.001 per share
- Symbol
- AGIO on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 63,038,208
- Total 13F value
- $2,119,469,955
- Portfolio coverage rank
- 0.01%
- Share change
- +1,590,239
- Value change
- +$71,916,598
- Number of holders
- 230
- Shares outstanding
- 59,431,072
- SEC-reported price per share
- $28.05
- Insider filing price
- $28.05
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- AGIO - AGIOS PHARMACEUTICALS, INC. - Common Stock, Par Value $0.001 per share is tracked under CUSIP 00847X104.
- 230 institutions reported positions in Q1 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 237 to 230 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $1,667,804,671 to $2,119,469,955.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 230 institutions filings for Q1 2026.
Security key
00847X104
Latest holder period
Q1 2026
13F holders
230
13D/G owners
7
CIK / CUSIP context first
Open Q1 2026 holders
AGIO full holder history
AGIOS PHARMACEUTICALS, INC. SEC filings
AGIOS PHARMACEUTICALS, INC. company facts
AGIOS PHARMACEUTICALS, INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 00847X104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
AGIO
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Farallon Capital Partners, L.P. | 8.8% | -11% | $146,117,182 | -$14,583,696 | 5,159,505 | -9.1% | Dapice Joshua J. | 31 Dec 2025 |
| BlackRock, Inc. | 7.8% | $150,100,362 | 4,513,170 | BlackRock, Inc. | 30 Jun 2025 | |||
| STATE STREET CORP | 5.3% | $88,022,666 | 3,108,145 | STATE STREET CORPORATION | 31 Dec 2025 | |||
| VANGUARD CAPITAL MANAGEMENT LLC | 5.3% | $104,472,757 | 3,088,169 | Vanguard Capital Management | 31 Mar 2026 | |||
| Lynx1 Capital Management LP | 5.1% | $105,819,749 | 3,013,949 | Lynx1 Capital Management LP | 29 Apr 2026 | |||
| Paradigm Biocapital Advisors LP | 4.9% | -6% | $115,344,498 | -$6,198,499 | 2,873,555 | -5.1% | Paradigm BioCapital Advisors LP | 30 Sep 2025 |
| ARMISTICE CAPITAL, LLC | 4.6% | -13% | $95,358,760 | -$11,235,200 | 2,716,000 | -11% | Armistice Capital, LLC | 31 Mar 2026 |
As of 31 Mar 2026, 230 institutional investors reported holding 63,038,208 shares of AGIOS PHARMACEUTICALS, INC. - Common Stock, Par Value $0.001 per share (AGIO). This represents 106% of the company’s total 59,431,072 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
81%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 9.7% | 5,754,957 | +9.9% | 0% | $194,690,195 |
| FARALLON CAPITAL MANAGEMENT LLC | 9.6% | 5,684,000 | +10% | 1.3% | $192,289,720 |
| STATE STREET CORP | 5.7% | 3,364,879 | +8.3% | 0% | $113,719,376 |
| ARMISTICE CAPITAL, LLC | 4.6% | 2,716,000 | -11% | 3% | $91,882,280 |
| Erste Asset Management GmbH | 4.6% | 2,704,900 | -3.6% | 0.74% | $80,092,089 |
| D. E. Shaw & Co., Inc. | 4.5% | 2,681,169 | +46% | 0.07% | $90,703,947 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.4% | 2,632,316 | 0% | 0% | $89,051,250 |
| Lynx1 Capital Management LP | 4.4% | 2,611,568 | +3180% | 14% | $88,349,345 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.4% | 2,611,035 | 0% | 0% | $88,331,314 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 2.7% | 1,580,840 | +16% | 0.06% | $53,479,817 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 2.5% | 1,494,435 | -12% | 0.09% | $50,557,000 |
| T. Rowe Price Investment Management, Inc. | 2.5% | 1,488,740 | +166799% | 0.03% | $50,365,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.5% | 1,467,910 | +3.8% | 0% | $49,670,160 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2.3% | 1,344,953 | +18% | 0.06% | $45,499,760 |
| MPM BIOIMPACT LLC | 2.2% | 1,306,261 | +0.22% | 3.4% | $44,190,810 |
| Frazier Life Sciences Management, L.P. | 2.1% | 1,256,080 | -1.8% | 1.1% | $42,493,186 |
| GW&K Investment Management, LLC | 2% | 1,214,901 | +0.63% | 0.36% | $41,101,000 |
| DIMENSIONAL FUND ADVISORS LP | 1.9% | 1,151,614 | +15% | 0.01% | $38,940,060 |
| MORGAN STANLEY | 1.6% | 967,524 | +8.2% | 0% | $32,731,355 |
| GOLDMAN SACHS GROUP INC | 1.4% | 805,776 | -22% | 0% | $27,259,402 |
| Rock Springs Capital Management LP | 1.3% | 799,163 | 0% | 1.6% | $27,035,684 |
| Nuveen, LLC | 1.2% | 722,348 | +142% | 0.01% | $24,437,033 |
| JANE STREET GROUP, LLC | 1.2% | 685,240 | -39% | 0.02% | $23,181,669 |
| WELLINGTON MANAGEMENT GROUP LLP | 1.1% | 641,486 | +7.3% | 0% | $21,701,472 |
| CITADEL ADVISORS LLC | 1% | 619,613 | -54% | 0.01% | $20,961,508 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
49
Latest
Q1 2026
Rows shown
1-25 of 49
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 63,038,208 | $2,119,469,955 | +$71,916,598 | $33.83 | 230 |
| 2025 Q4 | 61,265,073 | $1,667,804,671 | -$303,649,463 | $27.22 | 237 |
| 2025 Q3 | 63,487,439 | $2,545,616,686 | +$81,769,351 | $40.14 | 216 |
| 2025 Q2 | 61,683,672 | $2,051,725,997 | +$65,237,829 | $33.26 | 211 |
| 2025 Q1 | 59,963,279 | $1,757,322,194 | -$10,187,060 | $29.30 | 216 |
| 2024 Q4 | 59,832,436 | $1,966,429,716 | +$37,958,970 | $32.86 | 221 |
| 2024 Q3 | 58,096,571 | $2,582,267,784 | -$8,181,474 | $44.43 | 204 |
| 2024 Q2 | 58,132,966 | $2,506,935,894 | -$125,225,015 | $43.12 | 203 |
| 2024 Q1 | 61,946,791 | $1,811,267,450 | +$89,235,062 | $29.24 | 183 |
| 2023 Q4 | 59,884,422 | $1,333,701,271 | +$15,853,345 | $22.27 | 167 |
| 2023 Q3 | 59,110,077 | $1,463,036,585 | -$8,921,651 | $24.75 | 142 |
| 2023 Q2 | 59,366,269 | $1,679,785,246 | +$16,420,594 | $28.32 | 150 |
| 2023 Q1 | 58,996,438 | $1,355,139,176 | -$9,985,145 | $22.97 | 161 |
| 2022 Q4 | 59,442,573 | $1,669,125,079 | +$45,133,345 | $28.08 | 156 |
| 2022 Q3 | 57,972,960 | $1,639,524,356 | -$46,396,034 | $28.28 | 155 |
| 2022 Q2 | 59,017,906 | $1,308,562,484 | -$21,425,021 | $22.17 | 143 |
| 2022 Q1 | 59,895,743 | $1,743,443,247 | +$19,219,573 | $29.11 | 146 |
| 2021 Q4 | 59,210,281 | $1,947,305,194 | -$73,787,635 | $32.87 | 148 |
| 2021 Q3 | 60,890,488 | $2,810,077,563 | -$244,072,957 | $46.15 | 157 |
| 2021 Q2 | 65,926,694 | $3,632,531,095 | +$51,380,893 | $55.11 | 179 |
| 2021 Q1 | 65,233,267 | $3,366,007,585 | +$56,136,770 | $51.64 | 168 |
| 2020 Q4 | 64,981,734 | $2,817,090,446 | -$19,419,372 | $43.33 | 189 |
| 2020 Q3 | 65,869,834 | $2,304,359,620 | -$101,763,130 | $35.00 | 206 |
| 2020 Q2 | 67,492,943 | $3,609,431,770 | -$76,258,753 | $53.48 | 205 |
| 2020 Q1 | 69,390,256 | $2,461,883,479 | +$6,215,421 | $35.48 | 188 |